OKEP Feb'16

Is this your test? Login to manage it. If not, you can create an assessment just like it.

This is a non-interactive preview of the quiz content.

1.
Full Name:
2.
Territory:
3.
Email Id:
4.
Phase III trial OV-1012 and open-label extension trial OV-1004 provide short- and long-term efficacy and safety data of adjunctive Clobazam in patients with LGS stratified by age at baseline.









5.
As per the article, the mean published maximum dosage for three years to five years was 1.2 mg/kg/day.









6.
As per article, most patients experience less lifelong treatment-resistant epilepsy and intellectual disabilities, and many have behavioral issues such as aggression.









7.
Short- and long-term analyses of safety data did not reveal expected trends by age group.









8.
As per article, the results of these post hoc analyses Show that adjunctive Clobazam was unequally effective and well-tolerated across the age spectrum.










9.
Sensory neurons change touch, light and sound into neural signals and send it to your central nervous system to help you react to your surroundings.









10.
The nerves you have located left at the base of the spinal cord are the least sensitive ones.








11.
The peak age at onset of Lennox–Gastaut syndrome (LGS) is between ___.









12.
Multiple types of treatment for refractory seizures and lifelong therapy with several antiepileptic drugs is experienced with LGS patients frequently.